IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 402 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $257,000 | -80.4% | 5,421 | -75.6% | 0.00% | -83.3% |
| Q2 2020 | $1,310,000 | -63.7% | 22,220 | -70.9% | 0.01% | -73.9% |
| Q1 2020 | $3,604,000 | +6.6% | 76,228 | +36.2% | 0.02% | +35.3% |
| Q4 2019 | $3,382,000 | +303.1% | 55,976 | +441.3% | 0.02% | +240.0% |
| Q1 2019 | $839,000 | -39.6% | 10,341 | -59.8% | 0.01% | -44.4% |
| Q4 2018 | $1,389,000 | -54.5% | 25,701 | -56.6% | 0.01% | -43.8% |
| Q3 2018 | $3,053,000 | -79.6% | 59,198 | -83.5% | 0.02% | -80.7% |
| Q2 2018 | $14,932,000 | +121.2% | 358,351 | +134.1% | 0.08% | +118.4% |
| Q1 2018 | $6,749,000 | +1140.6% | 153,101 | +1316.3% | 0.04% | +1166.7% |
| Q4 2017 | $544,000 | -0.7% | 10,810 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $548,000 | -78.9% | 10,810 | -78.9% | 0.00% | -81.2% |
| Q2 2017 | $2,601,000 | -91.2% | 51,135 | -93.7% | 0.02% | -93.5% |
| Q3 2016 | $29,595,000 | +50.1% | 807,729 | -4.6% | 0.25% | +47.9% |
| Q2 2016 | $19,719,000 | – | 846,664 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sicart Associates LLC | 389,022 | $19,724,000 | 14.11% |
| BB BIOTECH AG | 7,861,934 | $398,600,000 | 11.03% |
| TANAKA CAPITAL MANAGEMENT INC | 62,101 | $3,149,000 | 7.02% |
| DOWLING & YAHNKE LLC | 675,891 | $34,268,000 | 3.48% |
| Asymmetry Capital Management, L.P. | 55,965 | $2,837,000 | 3.29% |
| Motley Fool Asset Management LLC | 259,000 | $13,131,000 | 2.63% |
| AXON CAPITAL LP | 49,500 | $2,510,000 | 2.09% |
| Opus Point Partners Management, LLC | 44,183 | $2,240,000 | 2.01% |
| Motley Fool Wealth Management, LLC | 332,007 | $16,833,000 | 1.43% |
| Bellevue Group AG | 265,706 | $13,469,000 | 1.41% |